Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues.

Internal and emergency medicine - 1 Mar 2007

Bencardino K, Manzoni M, Delfanti S, Riccardi A, Danova M, Corazza G R

Abstract excerpt

The medical treatment of non-small-cell lung cancer (NSCLC) has progressively changed since the introduction of "targeted therapy". The development of one of these molecular drug categories, e. g., the epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) selective inhibitors, such as the orally active gefitinib and erlotinib, offers an interesting new opportunity. The clinical response rates obtained with...

Topics

Carcinoma, Non-Small-Cell Lung
ErbB Receptors
Humans
Lung Neoplasms
Mutation
Prognosis

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 17551677
DOI: 10.1007/s11739-007-0002-5
PMCID: PMC2780603

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-17551677-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues.PMID 17551677Read ↗

[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives].Semantic proximity Read ↗

Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.Semantic proximity Read ↗

[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.Semantic proximity Read ↗

Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?Semantic proximity Read ↗

Exploring adjuvant epidermal growth factor receptor inhibition in non-small cell lung cancer.Semantic proximity Read ↗

Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.Semantic proximity Read ↗

Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives.Semantic proximity Read ↗

Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly.Semantic proximity Read ↗

Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives.Semantic proximity Read ↗

Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.